Currently, there are 75.79M common shares owned by the public and among those 73.30M shares have been available to trade.
The company’s stock has a 5-day price change of 0.29% and -9.62% over the past three months. XENE shares are trading -1.73% year to date (YTD), with the 12-month market performance down to -15.58% lower. It has a 12-month low price of $35.53 and touched a high of $50.99 over the same period. XENE has an average intraday trading volume of 401.17K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.95%, -5.71%, and -4.86% respectively.
Institutional ownership of Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares accounts for 95.37% of the company’s 75.79M shares outstanding.
It has a market capitalization of $2.94B and a beta (3y monthly) value of 1.21. The earnings-per-share (ttm) stands at -$2.81. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.96% over the week and 3.72% over the month.
Analysts forecast that Xenon Pharmaceuticals Inc (XENE) will achieve an EPS of -0.84 for the current quarter, -0.84 for the next quarter and -3.54 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.95 while analysts give the company a high EPS estimate of -0.95. Comparatively, EPS for the current quarter was -0.64 a year ago. Earnings per share for the fiscal year are expected to decrease by -13.70%, and -17.70% over the next financial year.
Looking at the support for the XENE, a number of firms have released research notes about the stock. Raymond James stated their Outperform rating for the stock in a research note on October 10, 2024, with the firm’s price target at $50. H.C. Wainwright coverage for the Xenon Pharmaceuticals Inc (XENE) stock in a research note released on October 01, 2024 offered a Buy rating with a price target of $53. Citigroup was of a view on January 04, 2024 that the stock is Buy, while Robert W. Baird gave the stock Outperform rating on December 08, 2023, issuing a price target of $63. Cantor Fitzgerald on their part issued Overweight rating on October 24, 2023.
